CONTROL BIONICS LIMITED (ASX: CBL)
Health care · News and insights
CBL: $0.048 -5.88% · MC: $29M
Latest CBL announcements
Announcement Insights
Control Bionics Reaffirms FY27 Growth Outlook as NeuroStrip Reaches Four-Market Registration
Control Bionics reaffirmed its outlook for approximately 50% revenue growth in FY27, weighted to the second half, after unaudited revenue rose each month in the September quarter and exceeded the June quarter. The company said its current plan is funded through FY27 without another capital raising, with about $6 million in cash at quarter-end and a material reduction in operating cash outflows forecast for the next quarter. NeuroStrip’s Australian registration completes its rollout across four markets, shifting the company’s focus to securing customers and partners.
Updated 17 Nov 2026, 09:27 AM Sydney time
Sources
NeuroStrip registered as a Medical Device in AustraliaChange of Director's Interest Notice - SteeleLetter to Shareholders Bell Potter ConferenceChange of Director's Interest Notice - RixLess Than Marketable Parcel Sale FacilityQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-17 · Health care
CBL: $0.048 -5.88% · MC: $29M
Control Bionics’ NeuroStrip wearable device has been included on Australia’s medical device register as a Class I device, allowing the company to supply it locally. The registration adds Australia to the US, Great Britain and European markets where NeuroStrip is already registered; the company says its focus is now on winning customers and partners.
Updated 2026-11-17 09:17
Sources
NeuroStrip registered as a Medical Device in AustraliaComments
2026-11-16 · Health care
CBL: $0.051 -3.77% · MC: $29M
Control Bionics director Jeremy Steele acquired 399,859 ordinary shares on market, increasing his holding to approximately 5 million shares. His options holding was unchanged.
Updated 2026-11-16 08:24
Sources
Change of Director's Interest Notice - SteeleComments
2026-11-11 · Health care
CBL: $0.050 +0.00% · MC: $29M
Control Bionics will present at the Bell Potter Healthcare Conference on 18 November, with CEO Jeremy Steele set to discuss the company’s business update, growth strategy and near-term catalysts.
Updated 2026-11-11 12:03
Sources
Letter to Shareholders Bell Potter ConferenceComments
2026-10-30 · Health care
CBL: $0.052 +6.12% · MC: $29M
Control Bionics director Stephen Rix acquired one million shares on market, increasing his direct and indirect holding to 11 million shares. The purchase follows a separate company update reporting revenue growth through the September quarter and reaffirming expected revenue growth of 50% in FY27, weighted to the second half.
Updated 2026-10-30 13:29
Sources
Change of Director's Interest Notice - RixComments
2026-10-29 · Health care
CBL: $0.049 +0.00% · MC: $29M
Control Bionics said unaudited revenue rose each month in the September quarter and exceeded the June quarter, while it expects revenue growth of approximately 50% in FY27, weighted to the second half. Quarterly operating cash outflows included FY26 incentives and other one-off costs, with the company forecasting a material reduction in the next quarter; it reported cash at bank of approximately $6 million at quarter end and said its current plan funds operations through FY27 without another capital raising. Separately, it established a facility for eligible small shareholders to sell their holdings without brokerage or handling fees, with the company covering transaction costs.
Updated 2026-10-29 11:04
Sources
Less Than Marketable Parcel Sale FacilityQuarterly Activities/Appendix 4C Cash Flow ReportComments
Comments